| pubmed-article:17664482 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17664482 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:17664482 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:17664482 | lifeskim:mentions | umls-concept:C1334815 | lld:lifeskim |
| pubmed-article:17664482 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:17664482 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:17664482 | lifeskim:mentions | umls-concept:C0033522 | lld:lifeskim |
| pubmed-article:17664482 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:17664482 | pubmed:dateCreated | 2007-7-31 | lld:pubmed |
| pubmed-article:17664482 | pubmed:abstractText | Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD). However, in most patients, chemotherapy cannot be discontinued. | lld:pubmed |
| pubmed-article:17664482 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17664482 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664482 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17664482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664482 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17664482 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:17664482 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:ChevretSylvie... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:OksenhendlerE... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:MeigninVéroni... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:BoulangerEmma... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:GalicierLione... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:VerdonRenaudR | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:GérardLaurenc... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:ObadiaMartine... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:JacometChrist... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:Madelaine-Cha... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:AgbalikaFelix... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:17664482 | pubmed:author | pubmed-author:BéreznéAliceA | lld:pubmed |
| pubmed-article:17664482 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17664482 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17664482 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:17664482 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17664482 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17664482 | pubmed:pagination | 3350-6 | lld:pubmed |
| pubmed-article:17664482 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:meshHeading | pubmed-meshheading:17664482... | lld:pubmed |
| pubmed-article:17664482 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17664482 | pubmed:articleTitle | Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. | lld:pubmed |
| pubmed-article:17664482 | pubmed:affiliation | Department of Clinical Immunology, Laboratory of Virology, Paris VII University, Paris, France. laurence.gerard@sls.aphp.fr | lld:pubmed |
| pubmed-article:17664482 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17664482 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17664482 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664482 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664482 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664482 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664482 | lld:pubmed |
